

Indices	Value	Pts	Chg (%)
SENSEX	31369.34	123.78	0.40
NIFTY	9674.55	36.95	0.38
SGX NIFTY*	9655.00	(12.50)	(0.13)
DOW Jones	21320.04	(158.13)	(0.74)
S&P 500	2409.75	(22.79)	(0.94)
Nasdaq	6089.46	(61.40)	(1.00)
FTSE	7314.52	(53.08)	(0.72)
CAC	5152.40	(27.70)	(0.53)
DAX	12381.25	(72.43)	(0.58)
Shanghai Composite*	3201.46	(10.98)	(0.34)
Nikkei*	19965.78	(28.28)	(0.14)
Hang Seng*	25465.22	(56.75)	(0.22)

*As at 8.30 am

Most Active Call & Put Symbol	Strike Price	OI	Chg (%)
NIFTY	9700 CE	3726750	(0.83)
NIFTY	9600 PE	5610450	17.59

Commodity	Value	Pts	Chg (%)
NYMEX Crude (USD)	44.97	(0.55)	(1.21)
Brent Crude (USD)	47.54	(0.57)	(1.18)
Gold (INR)	28116	9.00	0.03
Silver (INR)	37452	110.00	0.29
Copper (INR)	382	(0.05)	(0.01)
Zinc (INR)	180	0.20	0.11
Cotton (INR)	20440	530.00	2.66

Currency	Value	Pts	Chg (%)
USD/Rupee	64.78	(0.01)	(0.00)
Euro/Rupee	73.86	(0.06)	(0.00)
Pound/Rupee	83.94	0.00	0.00
Euro /USD	1.14	(0.00)	(0.09)
Dollar Index	95.93	0.12	0.13

Volatility	Value	Pts	Chg (%)
CBOE VIX	12.54	1.47	13.28
India VIX	10.98	(0.17)	(1.52)

Interest Rates	Value	Bps change
India 10-Yr Yield	6.54%	(1)
US 10-Yr Yield	2.38%	6

Trade Statistics	BSE	NSE	F & O
Turnover (INR Crs)	3873.01	24730.71	891411.34
Advance (Nos)	1541 (54%)	966 (52%)	NA
Declines (Nos)	1180 (42%)	721 (44%)	NA
Unchanged	122 (4%)	82 (4%)	NA

Market Summary

The market ended on a positive note on Thursday. The market breadth was positive with 5 gainers for every 4 losers on BSE. 1541 shares advanced whereas 1180 shares declined and 122 shares were unchanged on BSE.

BSE Sensex gained 124 points or 0.4% to close at 31369. Nifty 50 was up 37 points 0.4% to settle at 9677. BSE Mid-Cap index advanced 45 points or 0.3% to settle at 14947. BSE Small-Cap index gained 49 points or 0.3% to settle at 15790.

Top gainer in BSE Sensex were SBI (2.2%), ITC (1.7%), Coal India (1.5%), Bharti Airtel (1.4%) and BHEL (1.3%) whereas top loser in BSE were Bajaj Auto (1.5%), M&M (1.3%), Sun Pharma (1.0%), Axis Bank (0.9%) and ONGC (0.8%).

US markets closed negative, Dow Jones Industrial Average closed at 21320, declining 158 points (0.7%), S&P 500 was down 23 points (0.9%) to close at 2410 and Nasdaq declined 61 points (1.0%) to settle at 6089.

European markets closed negative, FTSE declined 53 points (0.7%) to close at 7315 and CAC was down 28 points (0.5%) to close at 5152 and DAX lost 72 points (0.6%) to close at 12381.

Macro News

- According to World Gold Council, an increase in taxes on gold sales in India could curb short-term demand from the world's No. 2 consumer. Government move to ban cash transactions over INR 2 lakh from April 1 could hurt gold demand in rural areas where farmers often purchase the metal using cash due to limited access to cheques and electronic payment systems. Two-thirds of India's gold demand comes from rural areas, where jewellery is a traditional store of wealth.
- RBI has notified the norms to limit the liabilities of consumers for unauthorized electronic transactions in their bank accounts, establishing a safety net for the citizens amid the national drive toward digital transactions and rising incidents of fraud. Customer will be entitled to zero liability where the unauthorised transaction occurs due to negligence/deficiency on the part of the bank.

Institutional Activity	Cash	
	06-Jul	July 2017
FII (INR Crs)		
Buy	4317	15074
Sell	4332	16501
Net	(15)	(1427)
DII (INR Crs)		
Buy	2887	11398
Sell	2571	9757
Net	316	1642

FII Derivative Statistics (NSE)				
Particulars	Buy (INR Crs)	Sell (INR Crs)	OI (Nos)	Chg (%)
INDEX FUTURES	1454.43	1998.02	268877	(1.19)
INDEX OPTIONS	45856.82	44340.72	769661	3.27
STOCK FUTURES	7303.98	6407.64	1050979	0.18
STOCK OPTIONS	4072.75	3976.59	55294	13.21
Total	58687.98	56722.97		

Gainers & Losers	Price	Chg (%)
Gainers (INR)		
SBI	280.90	2.15
ITC	336.75	1.72
Coal India	251.25	1.52
Bharti Airtel	381.40	1.36
BHEL	136.05	1.34
Losers (INR)		
Bajaj Auto	2729.60	(1.52)
M&M	1367.00	(1.30)
Sun Pharma	544.90	(1.04)
Axis Bank	509.00	(0.93)
ONGC	161.40	(0.77)

Sectoral Performance	Value	Pts	Chg (%)
S&P BSE Small Cap	15789.67	49.07	0.31
S&P BSE Mid-Cap	14947.35	45.36	0.30
S&P BSE Auto	23860.38	88.42	0.37
S&P BSE BANKEX	26563.92	119.96	0.45
S&P BSE Capital Goods	17262.74	21.57	0.13
S&P BSE FMCG	10725.39	80.35	0.75
S&P BSE Healthcare	14237.91	17.43	0.12
S&P BSE IT	9858.23	(25.78)	(0.26)
S&P BSE Metals	11773.03	37.61	0.32
S&P Oil & Gas	13438.68	(51.07)	(0.38)

Key News

IndiGo looking only at Air India's international and low-cost units

IndiGo is keen to buy only Air India's international operations and its low-cost arm Air India Express, if government does proceed with plans to carve up and sell the carrier.

Jubilant Life Sciences gets USFDA nod for anti-depressive drug

Jubilant Life Sciences has received final approval from the US health regulator for Bupropion Hydrochloride extended-release tablets, used for the treatment of major depressive disorder and prevention of seasonal affective disorder. The approved product is the generic version of Wellbutrin XL of Valeant.

Cabinet may decide on HPCL stake sale to ONGC this month

Cabinet is likely to consider this month sale of government's 51% stake in Hindustan Petroleum Corp. to ONGC for ~INR 26000 cr. HPCL has a market cap of ~INR 51,764 cr and buying government's entire 51.11% stake would entail an outgo of INR 26.450 cr. Another INR 13,450 cr would be required in case open offer for an additional 26% has to be made. ONGC has a cash reserve of INR 13,014 cr and to fund the government stake acquisition in HPCL, it will have to borrow at least INR 10,000 cr.

International Data

Country	Data	Forecast	Previous
US	Manufacturing Production	0.50%	0.20%

Sharad Avasthi

Head - Equity Research

sharad.avasthi@spagroupindia.com

Tel.: +91-022-4289 5600

Ext.635

Analyst Certification of Independence: The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of SPA Securities Limited, and have no bearing whatsoever on any recommendation that they have given in the Research Report. Disclaimer and Disclosures as required under SEBI (Research Analyst) Regulations, 2014: SPA Securities Limited (hereinafter refer as SPA Securities) and its affiliates are engaged in investment banking, investment advisory, stock broking, institutional equities, Mutual Fund Distributor and insurance broking. SPA Securities is a SEBI registered securities broking Company having membership of NSE, BSE & MCX for Equity, Future & Option, Currency Derivatives segment and Wholesale Debt Market. The Company is focused primarily on providing securities broking services to institutional clients and is empanelled as an approved securities broker with all the major Nationalised, Private and Co-operative banks, Corporate houses, Insurance Companies, Financial Institutions, Asset Management Companies and Provident Fund Trusts. Details of affiliates are available on our website i.e. www.spasecurities.com.

SPA Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. SEBI Reg. No. INH00002615.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in the last five years. We have not been debarred from doing business by any Stock Exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.

General Disclosures: This Research Report (hereinafter called "report") has been prepared by SPA Securities and is meant for sole use by the recipient and not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, (as defined under section 2(h) of securities Contracts (Regulation) Act.1956, through SPA Securities nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments.

This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by SPA Securities to be reliable, although its accuracy and completeness cannot be guaranteed. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. Any review, retransmission or any other use is prohibited.

The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. While we would endeavour to update the information herein on a reasonable basis, we are under no obligation to update the information. Also, there may be regulatory, compliance or other reasons that prevent us from doing so. Hence all such information and opinions are subject to change without notice.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using this Research Report. Neither SPA Securities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. SPA Securities may have issued other reports in the past that are inconsistent with and reach different conclusion from the information presented in this report.

SPA Securities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets.

A graph of daily closing prices of securities is available at www.nseindia.com and <http://economicstimes.indiatimes.com/markets/stocks/stock-quotes>. (Choose a company from the list on the browser and select the "three years" icon in the price chart).

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SPA Securities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes

Statements on ownership and material conflicts of interest, compensation - SPA and Associates

Disclosure of interest statement	Yes/No
SPA Securities/its Affiliates/Analyst/his or her Relative financial interest in the company	No
SPA Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month immediately preceding the date of the publication of the research report or date of public appearance.	No
Investment banking relationship with the company covered	No
Any other material conflict of interest at the time of publishing the research report	No
Receipt of compensation by SPA Securities or its Affiliated Companies from the subject company covered for in the last twelve months:	
• Managing/co-managing public offering of securities	
• Investment banking/merchant banking/brokerage services	No
• products or services other than those above	
• in connection with research report	
Whether Research Analyst has served as an officer, director or employee of the subject company covered	No
Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company:	No

SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9

For More Information Visit Us At : www.spasecurities.com

SPA CAPITAL SERVICES LIMITED

Investment Advisory services,
AMFI Reg. No. ARN-007

SPA Capital Advisors Limited

SEBI registered Category-1
Merchant Bankers
SEBI Regn. No. INM000010825

SPA COMTRADE PRIVATE LIMITED

SPA INSURANCE BROKING SERVICES LTD.

Direct Broker for Life and General
Insurance Broking
IRDA Lic. Code No. DB053/03

SPA Securities Ltd

NSE Cash
NSE Future & Option
NSE Currency Derivatives
BSE Cash
BSE Currency Derivatives
MCX-SX Cash
MCX-SX Future & Option
MCX-SX Currency Derivatives
Mutual Fund
CDSL DP
NSDL DP
SEBI Research Analyst

SEBI Reg. Nos.

INB231178238
INF231173238
INE231178238
INB011178234
INE011178234
INB261178231
INF261178231
INE261178238
ARN 77388
IN-DP-CDSL-485-2008
IN-DP-NSDL-316-2009
INH100002615